임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
60건 표시 (상위 60건)
- 2상모집 중단 (진행 중)· Arthritis, RheumatoidA Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Hidradenitis SuppurativaStudy to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Pulmonary Arterial HypertensionA Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Hypertension, PulmonaryExtension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Human Immunodeficiency Virus Type 1 (HIV-1) InfectionA Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Gastrointestinal CancerA Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Advanced Solid TumorA Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Metastatic Breast CancerStudy of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Classical Hodgkin Lymphoma RecurrentA Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Colorectal CancerPhase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Non-alcoholic Fatty Liver DiseaseA Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Renal Cell CarcinomaA Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
리드: 머크(MSD) · 협력: 모더나
- 2상모집 중단 (진행 중)· Malignant Pleural MesotheliomaStudy of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Stage IIIB(N2) Non-small Cell Lung CancerPembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Metastatic Triple-Negative Breast CancerPhase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Hodgkin LymphomaPET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Endometrial CancerNeo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Squamous Cell CarcinomaA Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Metastatic Pancreatic Ductal AdenocarcinomaBXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Breast CancerA Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Non-squamous NSCLCPembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Ovarian Squamous Cell CarcinomaAssessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Ovarian CancerSafety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Pulmonary HypertensionFrespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Esophagogastric AdenocarcinomaEvaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Colorectal CancerPembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Ovarian CancerONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Uveal MelanomaOlaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Carcinoma, HepatocellularPembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Ovarian Clear Cell CarcinomaPembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Melanoma Stage IVA Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Malignant MelanomaBinimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Squamous Cell Carcinoma of Head and NeckPembrolizumab Plus Olaparib in LA-HNSCC
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Melanoma, UvealLenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Malignant Neoplasm of BreastComprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Microsatellite Stable Metastatic Colorectal CancerA Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
협력: 일라이 릴리, 머크(MSD)
- 2상모집 중단 (진행 중)· Classical Hodgkin LymphomaFitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Chronic Lymphocytic LeukemiaA Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Lymphoma, Large B-Cell, Diffuse (DLBCL)A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Muscle Invasive Bladder CarcinomaPembrolizumab in Muscle-invasive Bladder Cancer
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Metastatic Colorectal CancerA Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
리드: 화이자 · 협력: 일라이 릴리, 머크(MSD)
- 2상모집 중단 (진행 중)· Metastatic Uveal MelanomaEfficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Effect of DrugDocetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Non-squamous Non-small-cell Lung CancerLenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Diffuse Large B Cell LymphomaPembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Advanced Urothelial CarcinomaA Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Non-small Cell Lung CancerStudy of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
리드: 길리어드 · 협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Extensive-stage Small-cell Lung CancerIfinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Ovarian CancerStudy of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Squamous Cell Carcinoma of LarynxStudy of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Thyroid CancerPhase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Lymphoma, Extranodal NK-T-CellPembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Breast CancerA Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Uterine CarcinosarcomaA Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· NSCLCA Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
협력: 머크(MSD)
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.